Medical devices, healthcare technology and the business of care
PMA approval · P250033

NEXUS Aortic Arch Stent Graft System

Endospan , Ltd. · Decision date Apr 2, 2026

MEDTECHLEDGER EXPLANATIONP250033

What did the FDA approve?

FDA approved PMA P250033 for the NEXUS Aortic Arch Stent Graft System from Endospan, Ltd. The approval statement describes the device as indicated for endovascular treatment of chronic dissections involving the aortic arch in patients at high risk for open surgical repair who have appropriate anatomy.

The database entry does not include a supplement type or supplement reason, so no changed item or modification to an earlier PMA is identified. The statement reports the device's indicated purpose but does not provide independent proof of safety or clinical effectiveness. Specific information absent from the record includes any prior PMA relationship, clinical data, or anatomical criteria defining appropriate anatomy.

FDA approval order statement

for the NEXUS Aortic Arch Stent Graft System. This device is indicated for the endovascular treatment of chronic dissections involving the aortic arch in patients who are at high risk for open surgical repair and who have appropriate anatomy
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Apr 2, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250033
Regulatory pathway
Premarket approval application
Product code
SDZ
Decision code
APPR
Decision date
Apr 2, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Endovascular System for Treatment of Ascending Aorta and Aortic Arch Lesions.

Product code
SDZ
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250033 received

    Application receipt date recorded by FDA.

  2. P250033 · FDA decision

    APPR

  3. P250033/S001 · Related supplement

    NEXUS Aortic Arch Stent Graft System

  4. P250033/S002 · Related supplement

    NEXUS Aortic Arch Stent Graft System

  5. P250033/S004 · Related supplement

    NEXUS Aortic Arch Stent Graft System

Timeline entries are records held by MedtechLedger for P250033. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250033

Product / regulatory recordCompanyPathwayDecision dateSource
Endospan , Ltd.PMA supplementMay 20, 2026FDA
Endospan , Ltd.PMA supplementJul 24, 2026FDA
Endospan , Ltd.PMA supplementSep 21, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Endospan , Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
105 Alta Meadows Rd., Alta, WY, 83414

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records